What is the recommended treatment for moderate left‑sided ulcerative colitis?

Treatment of Moderate Left-Sided Ulcerative Colitis

For moderate left-sided ulcerative colitis, start with combination therapy of oral 5-ASA (2-3 g/day) plus rectal 5-ASA enemas (at least 1 g daily), as this provides superior remission rates compared to oral therapy alone. 1

First-Line Therapy Algorithm

Initial Treatment Strategy

• Combination therapy (preferred): Oral mesalamine 2-3 g/day PLUS rectal 5-ASA enemas ≥1 g daily 1

  • The rectal component is critical for left-sided disease, as topical 5-ASA achieves higher remission rates than oral therapy alone 2
  • Rectal 5-ASA enemas reach the splenic flexure, making them ideal for left-sided distribution 3
  • Once-daily dosing of oral mesalamine is acceptable for convenience 2

• Alternative monotherapy options (if patient refuses rectal therapy):

  • Oral mesalamine 2-3 g/day alone 1
  • Rectal 5-ASA enemas alone (≥1 g daily) 2

Important caveat: Patients with moderate disease activity should preferentially receive combination therapy from the start rather than oral monotherapy, as they benefit most from the enhanced efficacy 1.

Assessment Timeline and Treatment Escalation

When to Reassess

Evaluate response at 4-8 weeks after initiating 5-ASA therapy 2. If inadequate symptomatic response, escalate treatment immediately.

Second-Line Options for 5-ASA Failure

Do NOT switch between different oral 5-ASA formulations - this is ineffective 2.

Instead, escalate to:

1. High-dose combination therapy: Oral mesalamine >3 g/day (up to 4.8 g/day) PLUS rectal mesalamine 1

2. If still inadequate response, add corticosteroids:

   • Oral prednisone 40 mg daily (strong recommendation) 2
   • Alternative: Budesonide MMX 9 mg daily (fewer systemic side effects, but slightly less effective) 2
   • Reassess within 2 weeks of starting corticosteroids 2

3. For patients who fail rectal mesalamine specifically: Consider rectal corticosteroid enemas/foam as alternative topical therapy 2

Critical Pitfalls to Avoid

• Never use corticosteroids for maintenance therapy - they are ineffective and cause significant adverse effects with prolonged use 2
• Do not use thiopurine or methotrexate monotherapy for induction - they are too slow-acting and ineffective 2
• Avoid delaying escalation - if no response to optimized 5-ASA therapy (high-dose oral + rectal) within 4-8 weeks, move to corticosteroids or advanced therapies

Third-Line: Advanced Therapies

For patients who fail corticosteroids or become corticosteroid-dependent:

Biologic therapy is indicated 2:

• Anti-TNF agents (infliximab, adalimumab, golimumab)
• Vedolizumab
• Ustekinumab
• JAK inhibitors (tofacitinib, upadacitinib) - FDA recommends after TNF failure 4
• S1P modulators (ozanimod, etrasimod)

Combination with immunomodulator: When starting anti-TNF therapy, combine with thiopurine or methotrexate rather than using as monotherapy for better induction rates 2.

Evaluate response to biologics at 8-12 weeks 2.

Maintenance Strategy

Once remission is achieved:

• Continue the same therapy that induced remission 2
• If remission achieved with oral 5-ASA: maintain with ≥2 g/day 2
• If remission achieved with rectal 5-ASA: continue same rectal therapy 2
• If remission achieved with combination: continue both oral and rectal 5-ASA 2

Key strength of evidence: The Toronto Consensus guidelines [2-2] provide strong recommendations (GRADE: Strong, moderate-quality evidence) for rectal 5-ASA as first-line therapy in left-sided UC, with rectal formulations demonstrating superior efficacy to oral therapy alone (pooled OR 8.30 vs placebo for symptomatic remission) 2. The 2019 AGA guidelines 1 reinforce combination therapy with conditional recommendations based on moderate-quality evidence.